Iizuka H, Ohmura K, Ishijima A, Satoh K, Tanaka T, Tsuda F, Okamoto H, Miyakawa Y, Mayumi M
Japanese Red Cross Saitama Blood Center, Tokyo.
Vox Sang. 1992;63(2):107-11. doi: 10.1111/j.1423-0410.1992.tb02495.x.
Hepatitis B virus (HBV) DNA was tested for in 294 blood units which had antibody against hepatitis B core antigen (anti-HBc) as the isolated serological marker of HBV infection. After amplification by polymerase chain reaction, HBV DNA was detected in 12 (6.9%) of 175 units that were positive for anti-HBc with hemagglutination inhibition titers greater than or equal to 2(6), significantly more often than in none of 119 units with titers less than or equal to 2(5) (p less than 0.01). These results indicate that the exclusion of blood units with isolated high-titer anti-HBc would be effective for further decreasing the risk of posttransfusion hepatitis B.
对294个血液单位进行了乙型肝炎病毒(HBV)DNA检测,这些血液单位以抗乙型肝炎核心抗原抗体(抗-HBc)作为HBV感染的唯一血清学标志物。经聚合酶链反应扩增后,在175个抗-HBc血凝抑制效价大于或等于2(6)呈阳性的单位中有12个(6.9%)检测到HBV DNA,这一比例显著高于119个效价小于或等于2(5)的单位中未检测到的情况(p<0.01)。这些结果表明,排除具有单独高滴度抗-HBc的血液单位将有效地进一步降低输血后乙型肝炎的风险。